Dry age-related macular degeneration: A currently unmet clinical need. - Wikidata - wikimedia - TriplyDB

Dry age-related macular degeneration: A currently unmet clinical need.

Dry age-related macular degeneration: A currently unmet clinical need.

http://www.wikidata.org/entity/Q34378033

about

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration Nitroxide pharmaceutical development for age-related degeneration and disease NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage.Principles of pharmacology in the eye.Transient acceleration of autophagic degradation by pharmacological Nrf2 activation is important for retinal pigment epithelium cell survival

P2860

Q26771522-A53FA4D0-EF5C-4853-9714-49560F27DE83 Q26776523-A1540968-8845-4FED-BD14-D1CD3885DD78 Q35408649-242A292C-42B9-4AEA-9040-3CF2ADD510E6 Q45871474-B2E9CF8D-891A-49A8-A3ED-E212EA84E06F Q58762776-4A51627F-13F8-436A-8B78-2BBAC2638BFB

P2860

Dry age-related macular degeneration: A currently unmet clinical need.

http://www.wikidata.org/entity/Q34378033

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Dry age-related macular degeneration: A currently unmet clinical need.

@ast

Dry age-related macular degeneration: A currently unmet clinical need.

@en

Dry age-related macular degeneration: A currently unmet clinical need.

@nl

type

label

Dry age-related macular degeneration: A currently unmet clinical need.

@ast

Dry age-related macular degeneration: A currently unmet clinical need.

@en

Dry age-related macular degeneration: A currently unmet clinical need.

@nl

prefLabel

Dry age-related macular degeneration: A currently unmet clinical need.

@ast

Dry age-related macular degeneration: A currently unmet clinical need.

@en

Dry age-related macular degeneration: A currently unmet clinical need.

@nl

P1433

Q34378033-C36E79B1-5F88-4C09-AB56-9BA9DAB14708

P1476

Q34378033-5BC217CC-C651-42CC-8663-07C89208D098

P2093

Q34378033-0201AE14-07C0-4F91-9B9E-35539743BCBC

Q34378033-7C420B0E-D9B8-4BC4-8DE0-8A07080B8289

P2860

Q34378033-06B0C372-A398-4AEA-93A0-2F238E22F512

Q34378033-09E385D8-5C2C-45B1-A6D1-F610EA76A725

Q34378033-0A124434-2B55-42DD-AA74-707B98E29B99

Q34378033-10D842F9-F246-4185-9796-4AD4661A4627

Q34378033-16A8FBFA-FF6B-41DD-BAFA-A061AFC44448

Q34378033-17393170-A633-4D92-998F-82EF4A7ED6BD

Q34378033-17DE596B-2FFB-4DC6-84B6-D176699E5E9D

Q34378033-1843BB28-8084-4220-98D7-0FAB7F989A21

Q34378033-18E46CEC-64E5-476F-B57C-AA5B42F3808B

Q34378033-18FDBF4A-212A-4332-8343-82F239DD51ED

P304

Q34378033-8DF0D859-0308-48AC-A99B-CA044C67681A

P31

Q34378033-A1C0C4DB-3179-44F9-8C0C-09125366BA33

P356

Q34378033-3CBF154A-0720-41FE-9BE0-9A958A1F97B3

P433

Q34378033-7650F4DB-E491-49F9-AED0-18049AE95D78

P478

Q34378033-126A5B08-0FF2-4ECD-AAFC-44C955C1D42B

P50

Q34378033-8C3CD750-85DB-43E9-B209-1A3D48242BE9

P577

Q34378033-8ED1904A-0945-4A32-8BF9-5DF9DBD9AF61

P5875

Q34378033-85B6233A-C6C0-4600-A2AE-474049DE0E7F

P698

Q34378033-174D96B9-B715-4F3E-8974-76E6DE5D226F

P932

Q34378033-5122BC0F-7396-411A-A6EE-5CBB5E517693

P356

IRDR.2012.V1.3.103

P1433

Intractable & Rare Diseases Research

P1476

Dry age-related macular degeneration: A currently unmet clinical need.

@en

P2093

Jean-François Girmens

http://www.w3.org/2001/XMLSchema#string

Katia Marazova

http://www.w3.org/2001/XMLSchema#string

P2860

A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration

Susceptibility genes for age-related maculopathy on chromosome 10q26.

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9

Complement factor H polymorphism in age-related macular degeneration

Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration

Retinopathy in mice induced by disrupted all-trans-retinal clearance

Body mass index and the incidence of visually significant age-related maculopathy in men

An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration

P304

103-114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5582/IRDR.2012.V1.3.103

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

José-Alain Sahel

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267730874

http://www.w3.org/2001/XMLSchema#string

P698

25343081

http://www.w3.org/2001/XMLSchema#string

P932

4204600

http://www.w3.org/2001/XMLSchema#string